1. Benda, N. (2012). Methodological issues in paediatric trial design (Presentation). URL http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/01/WC500120283.pdf
2. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. (May 1996). Guidance for industry: The content and format for pediatric use supplements. URL http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071957.pdf.
3. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. (November 2000). Guidance for industry: Recommendations for complying with the pediatric rule (21 CFR 314.55(a) and 601.27(a)) (Draft Guidance). URL http://www.fda.gov/ohrms/dockets/ac/03/briefing/3927B1_06_GFI-Complying%20with%20the%20Pediatric%20Rule.pdf.
4. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. (December 2000). Guidance for industry: E11 Clinical Investigation of Medicinal Products in the Pediatric Population. URL http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073143.pdf.
5. ASSESSING SENSITIVITY AND SIMILARITY IN BRIDGING STUDIES